Cargando…
Evidence is Lacking for the NHS England Interim Guidance for Managing Metastatic Non-small Cell Lung Cancer in the COVID-19 Pandemic
Autores principales: | Choudhury, M., Nageshwaran, S., Muthukumar, D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Ltd on behalf of The Royal College of Radiologists.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342028/ https://www.ncbi.nlm.nih.gov/pubmed/32684506 http://dx.doi.org/10.1016/j.clon.2020.07.003 |
Ejemplares similares
-
Looking a Gift Horse in the Mouth: Observations on NHS England's Interim Guidance on Pembrolizumab in Head and Neck Squamous Cell Cancer
por: Harrington, K.J., et al.
Publicado: (2020) -
Use of single-agent pembrolizumab as first-line treatment for non-small cell lung cancer with PDL1 status 50% as per NHS England interim guidance during the COVID-19 pandemic at Southend University Hospital
por: Sen, Rebecca, et al.
Publicado: (2021) -
RE: ISTH interim guidance to recognition and management of coagulopathy in COVID‐19
por: Akima, Satoshi, et al.
Publicado: (2020) -
Eradicating inconsistencies in isolation guidance for NHS healthcare workers
por: McVeigh, J., et al.
Publicado: (2021) -
ISTH interim guidance on recognition and management of coagulopathy in COVID‐19: A comment
por: Barrett, Christopher D., et al.
Publicado: (2020)